Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MergersTokenPostKorean, translatedFiled 20 h ago

[US Featured Stock] Insmed ($INSM) Surges 20.58% on the 19th... Sanofi ($SNY) Reportedly Considering Acquisition

Original headline[미국 특징주] 19일 인스메드($INSM) 20.58% 급등…사노피($SNY) 인수 검토

Open the sourceReported by TokenPost, tokenpost.kr, 19 November 2026, by 강이안

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

Insmed ($INSM) shares jumped 20.58% to close at $144.46 on the 19th after Bloomberg reported that Sanofi ($SNY) is exploring a potential acquisition of the biotech, with the stock touching $148.94 intraday and triggering a volatility halt (LULD). Sanofi is reportedly discussing the deal with advisers, though talks are at an early stage and could stretch over weeks, fall apart, or draw a rival bidder; neither company commented. The move matters because a Sanofi takeover would mark a major consolidation in respiratory and rare-disease biotech, handing the French pharma a commercial-stage asset in Insmed's brensocatib and Arikayce franchise. Watch for formal confirmation or denial from either side, any rival suitors, and the per-share premium implied by a deal.

Muhabbit's AI wrote this summary in its own words from TokenPost's report and translated it from Korean. It can get details wrong, so check the source.

Named in this story

Insmed, Sanofi, Bloomberg